GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed in both administration routes. Both IT and IV were ...

RNA-based technologies are a powerful molecular biology toolbox, empowering scientists to decipher the complexities of living ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the ...

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

体内原位聚合是指通过一系列可控化学反应（如氧化聚合、自由基聚合等）或者超分子自组装，在生物体内原位制备功能性高分子材料。这些聚合反应可在细胞内部、细胞表面、肿瘤微环境及皮下组织中发生。相比传统“外制内送”的材料递送方式，体内原位聚合具有显著优势：避免 ...

Presentation will take place during the “Developmental Therapeutics - Immunotherapy” session on May 31, 2025, from 3:00 – 6:00pm CT at McCormick Place, Chicago ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ ...

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

Holdings, Inc. (Nasdaq; COEP) (“Coeptis” or the “Company”), a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune and infectious ...